Health Condition 1: null- All children aged less than 13 years of age, with a definite history of snake bite or circumstantial evidence consistent with snake envenomation(syndromic approach)
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: All children aged less than 13 years of age, with a definite history of snake bite or circumstantial evidence consistent with snake envenomation(syndromic approach), attending the pediatric emergency services
Exclusion criteria
Exclusion criteria: 1. Children with chronic illnesses (e. g, chronic kidney disease or congenital heart disease) or decompensated cardiac failure. 2. Unknown bites. (Unknown bites shall be defined as bites in which the victims or their family members were sure it was not by a snake but something else). 3. Children without any local or systemic manifestations after snake bite. 4. Children with history of bronchial asthma or chronic liver disease. 5. Children already having AKI stage 3 (as per p-RIFLE classification)[8] or requiring dialysis at admission itself.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the incidence and severity of acute kidney injury among children received N-acetylcysteine as compared to children not received N-acetylcysteine as adjunctive management for snake envenomationTimepoint: At PICU and Hospital discharge. | — |
Secondary
| Measure | Time frame |
|---|---|
| MortalityTimepoint: At 28 days;To compare the incidence and severity of local swelling, cellulitis, hemorrhagic and neurotoxic manifestations, stay in PICU, ventilation, hospital and doses of anti-snake venom vials, and adverse effect among children receiving N-acetylcysteine versus children not receiving N-acetylcysteine as adjunctive management for snake envenomation. Timepoint: At PICU and hospital discharge. | — |
Countries
India
Contacts
JIPMER